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Abstract
Cytomegalovirus (CMV) is one of the most signiﬁcant viral pathogens during pregnancy and in immunocompromised patients. Antiviral
prophylactic strategies are limited by toxicities, drug–drug interactions and development of antiviral resistance. A safe and protective
vaccine against CMV is highly desirable in view of the potential positive impact on CMV-associated morbidity and mortality as well as
healthcare costs. Unfortunately, this demand could not be met in the past four decades although development of a CMV vaccine has been
ranked at the highest priority by the US Institute of Medicine. Multiple different vaccine candidates have been developed and evaluated in
phase I clinical trials and few succeeded to phase II trials. Nevertheless, two different vaccines showed recently promising results in trials
that studied healthy adults and immunocompromised solid-organ and bone-marrow transplant recipients, respectively. The gB/MF59 vaccine
exhibited a vaccine efﬁcacy of 50% in healthy, postpartum females. In transplant patients, gB/MF59 and the DNA vaccine TransVax both
limited the periods of viraemia and consequently the need for antiviral treatment. The success of these trials is encouraging and will
probably give new impetus to the development of an effective CMV vaccine. Sterilizing immunity may not be attainable in the near future and
may not be necessary for a CMV vaccine to have a signiﬁcant impact on health care as discussed in the present review.
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Signiﬁcance of Cytomegalovirus Infection
and Emerging Risk Groups
Cytomegalovirus (CMV) is one of the most signiﬁcant viral
pathogens during pregnancy and in immunocompromised
patients. CMV infection is the leading cause of congenital
viral infection in Western countries with an overall birth
prevalence of 0.64% [1]. Primary CMV infection occurs
during 1–4% of pregnancies with an associated rate of
congenital infection of 40–50% [2]. CMV-speciﬁc immunity
does not protect from intrauterine infection as 1% of
fetuses from CMV-seropositive pregnant women are
infected in the course of viral reactivation or superinfection
with a different CMV strain [2]. Infants with congenital CMV
infection are symptomatic at birth in 10% of cases and a
further 10–15% of infants will develop symptoms within
4 years postpartum [1,2].
The tremendous success of solid-organ and haematopoietic
stem cell transplantations add another growing group of
patients at risk for CMV disease. Particularly CMV-seronega-
tive transplant recipients who receive a graft from a
CMV-seropositive donor (D+ R–) are at high risk for severe
CMV disease [3]. Human immunodeﬁciency virus-infected
patients are mostly CMV-seropositive (>90%) and are there-
fore frequently at risk for CMV disease during periods of
intense immunodeﬁciency [4]. Fortunately, the advent of highly
active antiretroviral treatment reduced the incidence of CMV
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disease in these patients from being the most signiﬁcant
opportunistic infection before their development to a rarity
[3]. Progress in the treatment of autoimmune or haematolog-
ical diseases with immunomodulating drugs improved patient
management but put additional patient cohorts at risk for CMV
disease. For example, treatment of patients with chronic
lymphocytic leukaemia with the monoclonal antibody ale-
mtuzumab increases median survival by several years [5].
Alemtuzumab-associated lymphocyte and T-cell depletion,
however, results in CMV reactivation and disease in up to
66% of patients without antiviral prophylaxis [5]. Finally,
patients treated at intensive care units are also at increased
risk of CMV reactivation in the absence of a known immuno-
deﬁciency [6]. The reasons for reactivation and the clinical
signiﬁcance of CMV viraemia is poorly deﬁned in these patients
[6]. CMV reactivation in this cohort was associated with
adverse clinical outcome such as longer duration of mechanical
ventilation, prolonged hospitalization and increased all-cause
mortality [6].
In view of the signiﬁcant impact of CMV infection on health
care, a safe and protective vaccine against CMV is urgently
needed. Development of a CMV vaccine is ranked at the
highest priority by the US Institute of Medicine based on
avoidable economic costs—estimated annual savings would be
$4 billion for transplantations and congenital infections in the
USA alone [7]. However, this need could not be met during
four decades of CMV research.
Strategies for the Prevention of CMV
Disease
In the absence of an effective CMV vaccine, alternative
strategies were devised to reduce the risk of CMV infection
and disease. Hand and environmental hygiene is an essential
part in every effective infection control programme and may
also reduce transmission rates of CMV. CMV infection in the
ﬁrst 3 years of life is followed by viral excretion in urine and
saliva for up to 42 months [8]. Accordingly, CMV-seroneg-
ative mothers of CMV-infected children are at 20–25%
higher risk of primary CMV infection compared with
CMV-seronegative mothers of uninfected children and
become infected with a probability of at least 50% within
1 year after the child acquires the infection [8]. Effective
hygiene measures for CMV-seronegative mothers and
screening of their children for CMV infection could reduce
infection rates signiﬁcantly [8]. Still, effective interventions
also included avoidance of intimate contact of the CMV-sero-
negative mother with its child, which appears to be rather
drastic.
Several antiviral drugs have been licensed for treatment and
prophylaxis of CMV infection and disease (reviewed in [9]).
Development of viral resistance to these drugs, toxicities,
drug–drug interactions and inhibition of the host’s immune
response to CMV may limit signiﬁcantly the usefulness of these
drugs in the clinical setting [9]. To limit potential side-effects of
antiviral prophylaxis, the concept of pre-emptive therapy was
developed [10]. Pre-emptive therapy is based on the obser-
vation that viraemia is a prerequisite for development of CMV
disease. Hence, pre-emptive therapy involves serial testing for
CMV-DNA in blood samples and, in contrast to antiviral
prophylaxis, administration of antiviral drugs only in the case of
a positive test result [10]. Drug-related toxicities may be
reduced considerably with the use of pre-emptive therapy
although both preventive approaches have multiple beneﬁts
and disadvantages that stirred a controversy on the most
useful approach (reviewed in ref. [10]).
The CMV Vaccine Pipeline
Multiple candidate CMV vaccines have been developed during
the past four decades and several more are currently under
preclinical and clinical evaluation (Table 1). Phase I clinical trials
were carried out on almost a dozen vaccine candidates with
different antigens, formulations, adjuvants and routes of
administration. The stream of vaccine candidates, however,
diminishes to a trickle at advanced stages of clinical evaluation.
So far, the experience with only a single CMV vaccine
warranted a phase II clinical trial in healthy adults for
protection from CMV infection [11]. Two further recent
phase II trials aimed at modifying the course of CMV
reactivation or re-infection in immunocompromised patients
(therapeutic vaccination) [11,12]. Surprising to all scientists
involved [13], these recent CMV vaccine trials were successful
and showed for the ﬁrst time some light on the horizon.
Phase II Vaccine Studies in Healthy
Individuals
The gB/MF59 vaccine was developed in the early 1990s by
Chiron (Emeryville, California, USA) and later by Sanoﬁ
Pasteur (Paris, France). The vaccine is based on a puriﬁed gB
protein formulated with MF59, a squalene and water emulsion
adjuvant [13]. In a series of phase I clinical trials including
adolescents and adults as well as toddlers, the vaccine was
found to be safe and immunogenic (Table 1) [14,15]. A
vaccination schedule of 0, 1 and 6 months elicited the highest
titres of neutralizing gB-speciﬁc antibodies [16], antibody and
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T-cell responses could be boosted successfully in CMV-sero-
positive women [24], and gB/MF59 was signiﬁcantly more
immunogenic than the highest dose of gB adjuvanted with
aluminium hydroxide [14].
The extensive and promising experience gained in these
early studies warranted a phase II trial in young women of
child-bearing age. The patient population of this trial com-
prised postpartum, CMV-seronegative, predominantly Afri-
can-American (73%) women (Table 2). The advantage of this
population was a comparably high force of CMV infection.
CMV-seronegative mothers in earlier studies acquired CMV
between deliveries at a rate of c.6% per year and past CMV
infection reduced the congenital infection rate by around 67%
in subsequent pregnancies compared with the rate in new-
borns of CMV-seronegative women [25]. At months 0, 1 and
6, subjects received either the investigational vaccine or
placebo (Table 2) and were followed for a median period of
42 months. Subjects were screened for CMV infection by a
commercial ELISA that used whole virus lysate. To differen-
tiate immunity generated by the vaccine from that by infection,
sera were pre-absorbed with recombinant gB to eliminate
gB-speciﬁc antibodies, similar to the concept applied to the
diagnosis of hepatitis B infection [26].
The gB/MF59 vaccine was clearly more effective than
placebo in protecting from CMV infection. CMV infection
was diagnosed in 31/216 (14%) placebo and 18/225 (8%) CMV
gB vaccine recipients (p 0.02). The rate of CMV infection was
6.6/100 person-years in placebo recipients compared with 3.3/
100 person-years in vaccine recipients, an overall efﬁcacy of
50%. Congenital CMV infection occurred in 1/81 (1%) and 3/97
(3%) babies born, respectively, to CMV gB vaccine and placebo
recipients. During the ﬁrst 15 months of the follow-up period,
vaccinees had a signiﬁcantly higher probability of remaining
free of CMV infection than controls. Nevertheless, this
difference remained stable for the ensuing observation period.
Accordingly, the protective effect of the gB/MF59 vaccine may
be short-lived in concordance with phase I trials that showed
neutralizing antibody titres that declined rapidly half a year
after vaccination [14,16].
The measured vaccine efﬁcacy of 50% is clearly higher than
expected and lower than wished for from a clinical perspec-
tive. Still, is sterilizing immunity essential for a CMV vaccine to
have a signiﬁcant impact on CMV-associated morbidity and
mortality? In contrast to highly infectious viral pathogens such
as measles or rubella, CMV is poorly contagious [27]. The
estimated force of CMV infection ranges between 1.6 and 3.5/
100 persons/year in the general population of Western
countries and is considerably higher in non-Hispanic Blacks
and Mexican Americans and in groups with low household
income [28]. Accordingly, even modest rates of vaccinationT
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efﬁcacy (~60%) would be sufﬁcient to generate herd immunity,
interrupt transmission and eradicate CMV from the human
population [30]. Concomitant interventions such as education
and levelling of social disparities would very likely decrease the
force of infection further and increase the success of a CMV
vaccine.
Moreover, sterilizing immunity may not be required to
protect infants from the consequences of intrauterine CMV
infection. The evaluation of dried blood spots from newborn
biochemical screening (‘Guthrie’) cards for quantity of
CMV-DNA revealed a signiﬁcant positive correlation between
viral load and severity of sensorineural hearing loss [31].
Vaccinating adolescent females with a CMV vaccine that does
not protect from infection but from signiﬁcant periods of
viraemia in the child may still be a valuable prophylactic option
in addition to the use of antivirals in newborns, which
frequently cause signiﬁcant neutropenia [32].
Phase II Vaccine Studies in Immunocom-
promised Patients
Three phase II clinical trials have been completed in immuno-
compromised patients so far (Table 2). Two decades ago, the
ﬁrst one was conducted in D+ R– kidney transplant recipients
at high risk for CMV infection with the use of an attenuated
Towne strain of CMV [33]. Consistent with earlier phase I
studies, this vaccine did not prevent CMV infection, but severe
cases of CMV disease were observed only in the placebo group
[33]. Nevertheless, a limitation of this vaccine was its apparent
inefﬁciency to generate neutralizing antibodies [34].
In 2006, a trial of the gB/MF59 vaccine was initiated in
kidney and liver transplant patients to evaluate its effectiveness
with respect to reducing the incidence of end-organ disease
[11]. The patient population included CMV-seropositive and
CMV-seronegative recipients and donors, respectively.
Patients were followed for a median observation period of
95 days post-transplantation. One prerequisite for the feasi-
bility of this study was the use of pre-emptive therapy in
contrast to universal prophylaxis, which allowed the evaluation
of vaccine efﬁcacy without confounding by the antiviral
intervention. The low rates of end-organ disease observed
(1/78 patients) underlined the effectiveness of pre-emptive
therapy but made the deﬁnition of the co-primary endpoints—
safety and immunogenicity of the vaccine—necessary [11].
The gB/MF59 vaccine induced signiﬁcantly higher antibody
titres in CMV-seronegative and -seropositive subjects than in
placebo recipients. The proportion of patients who tested
positive for CMV-DNA anytime during the observation period
was similar in the two study groups. Still, high gB-antibody
titres correlated with shorter duration of viraemia (p 0.0022)
and, particularly in the D+ R– vaccine recipients at high risk for
CMV infection, duration of viraemia and number of days of
ganciclovir treatment were reduced [11].
The third CMV vaccine evaluated in a phase II trial, TransVax
[VCL-CB01, Vical (San Diego, California, USA)/Astellas
(Tokyo, Japan)], differs from gB/MF59 with respect to formu-
lation, antigens and target population. TransVax is a bivalent
DNA vaccine encoding the two CMV antigens pp65 and gB,
adjuvanted with poloxamer CRL1005 and benzalkonium chlo-
ride. CMV pp65 was included to induce T-cell responses and gB
was included to induce antibody and T-cell responses. The aim
of the phase II trial of TransVax was to boost pre-existing
immunity in CMV-seropositive bone-marrow transplant recip-
ients (therapeutic vaccination) [12]. Subjects received either
vaccine (n = 40) or placebo (n = 34) at day –5, 21–41, 84, 196
and were followed for 1 year post-transplantation (Table 2).
Similarly to the gB/MF59 trial, the main endpoint of this study
was signiﬁcant CMV-DNA detectable in blood from patients
and requiring antiviral therapy.
Occurrence and duration of CMV viraemia episodes were
signiﬁcantly reduced in these CMV-seropositive patients when
receiving the full vaccination schedule of TransVax. In addition,
the intervals between periods of viraemia were clearly longer
in vaccine recipients than in placebo recipients.
The observed efﬁcacy of TransVax is remarkable for several
reasons. (i) Donors of bone marrow were also CMV-sero-
positive in >50% of transplantations and therefore potential
sources for CMV superinfection with an additional viral strain.
Immunosuppressive or myeloablative therapies diminish the
response of pre-existing immunity to antigens and immune
maturation following primary infection is clearly prolonged
[35]. Accordingly, it may be hypothesized that the vaccine had
some protective effect also in cases of superinfection. (ii) The
successful vaccination strategy was attributed to the stimula-
tion of cell-mediated immunity to pp65, gB-speciﬁc humoral or
cellular immunity was not stimulated signiﬁcantly with use of
TransVax [12]. In a phase I trial in healthy CMV-seropositive
and CMV-seronegative adults, Transvax induced a signiﬁcant
antibody and/or T-cell response only in 46% of CMV-sero-
negative and in 25% of CMV-seropositive participants evalu-
ated [36]. In contrast, the success of the gB/MF59 vaccine trial
in solid-organ transplant recipients was deﬁned similarly by
virological end-points but attributed to the generation of
protective gB-antibody titres [11]. This difference between the
two studies underlines the importance of clinical end-points in
CMV vaccine trials, such as prevention of maternal–fetal
transmission of CMV or of CMV disease in immunocompro-
mised patients [13]. (iii) The equally high occurrence rate of
CMV disease recorded in both TransVax study groups is a
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reminder that sterilizing immunity may not be attainable in
immunocompromised patients. Still, a CMV vaccine may still
have a signiﬁcant clinical impact when the use of potentially
toxic antiviral drugs may be reduced, the efﬁcacy of established
prophylactic strategies improved, and the time of ﬁrst CMV
viraemia delayed to periods of less intense immunosuppres-
sion, as was the case in the TransVax study.
Future Directions in the Development of a
CMV Vaccine
Evaluation of the two successful CMV vaccines (gB/MF59,
TransVax) will be carried on soon in phase III trials (see www.
clinicaltrials.gov). Still, the use of laboratory-adapted CMV
strains as templates for vaccine antigens may be problematic.
AD169 and Towne have been extensively propagated on
ﬁbroblasts and harbour deletions, mutations and rearrange-
ments in the virus genome including a large deletion in the
AD169 genome encompassing all of the UL133-UL150 genes
and a frameshift in the UL131 gene [37]. Wang and Shenk
showed recently that an intact UL128-131 locus is important
for broadening viral tropism to epithelial and endothelial cells
[37]. Antibodies to the pentameric complex gH/gL/UL128-131
neutralize viral entry into epithelial cells and reduce the risk of
perinatal CMV transmission [37,38]. Interestingly, the penta-
meric complex of rhesus and human CMV also appears to play
a signiﬁcant role in the priming of T cells by inhibiting
responses to highly promiscuous, unconventional epitopes,
which would induce a broad major histocompatibility complex
class I-restricted and class II-restricted CD8+ T-cell response
[39].
In recognition of the immunological signiﬁcance of the
pentameric complex of CMV, part of the pentameric complex
is incorporated as antigen in two vaccines that are currently
under development. One vaccine is based on an alphavirus
replicon particle vaccine platform that generated in mice
broadly cross-reactive complement-independent CMV neu-
tralizing antibodies at higher titres than those elicited by gB
[40]. The other vaccine is based on a CMV virus with restored
expression of the pentameric complex (AD169-based revert-
ant) which showed a signiﬁcant increase of neutralizing
antibodies in rhesus macaques in comparison to the AD169
strain [41].
Recent CMV vaccine designs even focus on turning the
virus’ own immunomodulatory strategies against itself. For
example, NKG2D is a potent immune-activating receptor
expressed on NK cells, NKT cells, cd T cells and CD8 T cells.
CMV has evolved numerous mechanisms to evade
NKG2D-mediated immune response. Generation of recombi-
nant CMV encoding the ligand for an activating NK cell
receptor, however, results in a profoundly attenuated virus
strain that induces long-lasting immunity [42].
In conclusion, the success of recently completed clinical
trials is encouraging and is likely to give new impetus to the
development of a CMV vaccine. The low hanging fruits of
vaccine development against smallpox, polio, measles, mumps
or rubella have been picked but should not serve as standards
for a CMV vaccine. Nevertheless, the recent clinical trials
underline the fact that the development of a CMV vaccine with
a signiﬁcant impact on health care is feasible. Novel vaccine
technologies along with identiﬁcation of additional and poten-
tially even more immunogenic CMV epitopes carry a high
potential to improve CMV vaccine efﬁciency further.
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